TKIs targeting the VEGF receptor (VEGFR-TKIs) (i.e., sunitinib and regorafenib) and brutons tyrosine kinase (BTK) inhibitors (i.e., ibrutinib), increase bleeding risk through platelet dysfunction, thrombocytopenia, and interactions affecting coagulation pathways. The gene discussed is BTK; the disease is Thrombocytopenia.